Sector Expert: Mario Corso



Recent Quotes

"We expect FDA approval of ACRX's Zalviso at/near the July PDUFA date."

— Mario Corso, Mizuho Securities (1/16/14)
more >

"ACRX is a rare, undervalued company targeting a $1B market."

— Mario Corso, Mizuho Securities (1/6/14)
more >



Due to permission requirements, not all quotes are shown.